

FIG. 1




FIG. 2






FIG. 3




FIG. 4





FIG. 5

TRIMER:



TETRAMER:




FIG. 6




FIG. 7




FIG. 8





FIG. 9




6 M HCl, 110 °C, 24 HR., IN VACUO

NH₂-CH₂-CH₂-NH₂
ETHYLENEDIAMINE

HOOC-CH₂CH₂CH₂-NH₂
GABA (=γ-ABA)

PEPTIDE AMINO
ACIDS

NH₂CH-COOH




S-2-(2R,2S-SUCCINYL)-L-CYSTEINE

FIG. 10

08/22/99 14:28:28

CHANNEL A INJECT 08/22/99 14:28:28



+ = PTC-(S-2-(2R,2S-succinyl)-L-Cys
• = PTC-GABA

FIG. 11

CONJUGATE PEPUDE SUBSTITUTION DENSITY EQUATION

NO MOLECULES PEPUDE/MOLECULE DEXAMINE

$$= \frac{\text{PMOLES PEPTIDE VIA AAA}}{\text{PMOLES DEXAMINE(=BACKBONE) VIA AAA}}$$


-----> NON-COVALENTLY LINKED PEPTIDE INCREASES NUMERATOR!

-----> LOSS OF DEXAMINE DURING:


-GMBS DERIVITIZATION
-G-25 COLUMN PURIFICATION
- REACTION MIXTURE TRANSFERS

DECREASES NUMERATOR

FIG. 12



S-2-(2R,2S-SUCCINYL)-CYSTEAMINE



S-2-(2R,2S-SUCCINYL)-DL-HOMOCYSTEINE

FIG. 13




FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19




FIG. 20




FIG. 21




FIG. 22




FIG. 23




FIG. 24




FIG. 25




FIG. 26




FIG. 27




FIG. 28




FIG. 29




FIG. 30




FIG. 31




FIG. 32




FIG. 33

CELLS PRODUCING
ANTI-FL IgG
ANTIBODY PER 300,00
SPLEEN CELLS




FIG. 34

PERCENT REDUCTION
OF NUMBER OF
CELLS SECRETING
ANTI-FL IgG ANTIBODY




FIG. 35






FIG. 36



PENICILLIN



PENICILLOYL

FIG. 37




FIG. 38a




FIG. 38b




FIG. 39

SERUM ANTI-BSA
IgM LEVEL,
mOD/MIN




FIG. 40




FIG. 41

2017-04-26




FIG. 42




FIG. 43




FIG. 44




FIG. 45




FIG. 46

SPECIFIC SERUM
IgM LEVEL,
mOD/MIN




FIG. 47




FIG. 48




FIG. 49




FIG. 50




FIG. 51




FIG. 52a

20171014 0440




FIG. 52b

20240424




FIG. 53a




FIG. 53b




FIG. 54a

20744460





FIG. 54b



TIME, SEC./16)

FIG. 55